UPMC Hillman is an NCI-designated Comprehensive Cancer Center: What this means for patients
For patients, treatment at an NCI-designated Comprehensive Cancer Center can mean better outcomes, according to a 2015 study of individuals with newly diagnosed adult-onset cancer.
'The advances that have been made of the past 10-plus years have really changed the landscape of cancer care,' says Stanley M. Marks, MD, UPMC Hillman's chairman. 'We can successfully treat difficult cancers now that 10 or 15 years ago, we never dreamt that we could. But in addition to better outcomes, the quality of life has improved.'
NCI designation is earned, not paid for or determined by peer nomination. Centers must demonstrate excellence in research across multiple branches of science and among a multidisciplinary team. Every five to seven years, UPMC Hillman undergoes a rigorous evaluation—including an extensive grant application and assessments of its research activities—to maintain its status.
expand
From Bench to Bedside
More than 300 UPMC Hillman scientists work together to investigate all aspects of cancer, from how it develops and behaves at the molecular level to how genetic, environmental, and lifestyle factors influence someone's cancer likelihood. The team engages in bench-to-bedside practices, working collaboratively with physicians to translate promising laboratory findings into new and better therapies, diagnostic tools, and prevention strategies.
UPMC Hillman experts have made groundbreaking discoveries and pioneered new treatments to improve patient care, including:
Discovering two of the seven known cancer-causing viruses
Being the first to use natural killer cells, a type of immune cell, against cancer
Demonstrating that changing the gut microbiome through fecal transplant can enable patients with melanoma who did not previously respond to immunotherapy to successfully respond
Being the first to use a synthetic vaccine called MUC-1 against cancer
Creating national guidelines for exercise as a means to reduce the severity of chemotherapy symptoms
Developing the first vaccine targeting ductal carcinoma in situ, a type of pre-invasive breast cancer
Nationally Recognized Care in Local Communities
UPMC Hillman's NCI designation extends throughout its entire network, which includes nearly 80 locations in communities throughout Pennsylvania, Ohio, New York, and Maryland, well beyond its flagship facility in Pittsburgh. This means that patients can receive the latest evidence-based care and ongoing support with little or no need to travel.
'We strive for all our locations to deliver the same care the patients would receive if they came to Pittsburgh,' Dr. Marks says. 'For the most part, 90% of cancer care can be delivered in the community, and we want patients to be treated closer to home.'
At UPMC Hillman Cancer Center, we understand the complexity of cancer. Learn more about our research and clinical trials here.
UPMC Hillman Cancer Center is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is harnessing the expertise of physicians, scientists and allied health care professionals who deliver comprehensive clinical care, lead cutting-edge research, train future generations of cancer experts and engage with our communities to detect, treat and prevent cancer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Mom's Urine Turns Black After Taking Weight-Loss Meds to Slim Down Before Vacation: ‘I Thought I Could Die'
NEED TO KNOW A Scottish mom of two bought a GLP-1 medication online to lose weight for a vacation, saying she was 'fed up with not fitting in my clothes' Claire Reed, 49, caims the medication made her too nauseous to eat or drink, and was so dehydrated 'my urine was black' Her children brought her to the hospital after she passed out, and says 'I thought I could die'A mom became so dehydrated while taking weight-loss medication she bought online that her urine turned black, leading to her being hospitalized and fearing for her life. Claire Reed, 49, was planning a vacation with her daughter, and admitted 'I was fed up with not fitting in my clothes,' according to Daily Mail. Although the mom of two, who hails from the Scottish city of Aberdeen, says she wasn't 'that big' — she was classified as overweight, not obese — she decided to buy weight-loss medication via an online pharmacy in March. She didn't see a doctor; Rather, she just filled out an online questionnaire. When she received the medication, she admitted, 'There were no instructions on how to deal with it.' In the first few months of taking the medication, Claire says she lost nearly 60 lbs. But as time went on, she began to feel nauseous every time she ate or drank — would sporadically lose consciousness. 'I couldn't eat, so I was just collapsing because I had no food or water. I wasn't able to process anything in my body. I felt very sick and had no appetite,' Claire says. 'I was never going to the toilet and when I did my urine was black. I had to force myself to drink water.' She says she was "embarrassed," and hid her struggles from her family and friends. It wasn't until she had an episode in front of her son and daughter that her children began 'panicking' and took their mother for urgent medical care. 'They put me on an IV. I told them I've been taking the jab and they said this could be what it is,' Claire said, sharing that the doctors cautioned her about online pharmacies. 'The people selling it to you can't see you, they're just asking a quick questionnaire. And then you're left on your own.' She's stopped taking the medication, but says she's struggled to regain any appetite. 'I'm still not hungry and still not gaining weight. Any food at all makes me feel sick,' Claire said. 'I was very scared, your body needs food and fluid. I thought I could die.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Business Wire
2 hours ago
- Business Wire
Chai Discovery Announces $70 million Series A To Transform Molecular Design
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round. The fundraise was led by Menlo Ventures, including investment from their Anthology Fund, a joint partnership with Anthropic to identify and back promising AI companies, with participation from new investors Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and others. It also included existing investors Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam, among others. 'Progress towards game-changing drugs and treatments is far too slow, stymied by costly trial-and-error experiments,' said Joshua Meier, CEO and co-founder. 'Chai Discovery exists to push the boundaries of what's possible in this field, applying frontier AI to transform biology from science to engineering, so that breakthroughs can be designed rather than simply discovered.' Chai was founded in 2024 by Joshua Meier (ex AI drug discovery firm Absci; Facebook AI; OpenAI), Jack Dent (ex Eng and Product leader at Stripe), and AI researchers Matthew McPartlon and Jacques Boitreaud. Mikael Dolsten M.D., PhD., the former Pfizer Chief Scientific Officer responsible for advancing 150 molecules into clinical trials and delivering 36 approved medicines, is joining the company's board of directors. 'I'm proud to join Chai Discovery and redefine biology from science into engineering,' Dr. Dolsten said. 'This is going to be an incredible journey with an incredible team.' Last year, the company closed a $30 million seed round led by Thrive Capital, OpenAI, and Dimension. Soon after, they released Chai-1, an open-source foundation model for molecular structure prediction that performs at the state-of-the-art Last month, the team unveiled a further leap in AI-driven drug discovery with their Chai‑2 breakthrough, delivering fully de novo antibody design with a near-20% hit rate. By contrast, traditional lab based methods often have to screen millions to billions of antibodies to find hits, and the previous state of the art for computational methods was only 0.1%. When inputting only the target antigen and epitope, Chai‑2 can generate successful binders from scratch against a wide variety of targets. This means that scientists working on a target antigen, a specific disease-causing protein such as a virus or type of cancer, can use Chai-2 to design, from scratch, completely new antibodies that can hit the right spot. 'Before Chai-2, the process was not unlike searching a giant bunch of keys for the right fit for a lock—but there are millions of keys,' said Matthew McPartlon, co-founder. 'Now, it's like having a master locksmith design exactly the right shape key, based only on your description of the lock. A company had spent more than three years and over $5m on a problem. With Chai-2, we were able to find an experimentally validated solution within two weeks.' The funding will be used to further develop the Chai platform, applying it toward previously inaccessible targets, and onboarding select partners. 'Chai is an exceptional technical team building foundation models for biology to transform drug discovery,' said Greg Yap, Partner at Menlo Ventures. 'Chai-2 demonstrates amazing progress in antibody design, and we have seen a meaningful fraction of the biotech industry already apply for Chai-2 access. At Menlo, we invest deeply in both AI foundation models and technology-enabled biology–we believe Chai can help create better medicines faster.' For more information on Chai Discovery and its platform, visit Chai Discovery builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, the fundamental building blocks of life. Its mission is to transform biology from science into engineering. The team hails from pioneering research and applied AI companies such as OpenAI, Meta FAIR, Stripe, and Google X, and is backed by top investors including OpenAI, Thrive Capital, Menlo Ventures and Dimension.
CNBC
2 hours ago
- CNBC
Eli Lilly earnings are coming Thursday. Here's what top analysts expect
Many on Wall Street expect that Novo Nordisk 's loss has been Eli Lilly 's gain, and this will be good news for the Zepbound maker's second-quarter results. Novo Nordisk's stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and Wegovy for obesity. The company has said its business has been hurt by competition from compounding pharmacies, which are making knock-off versions of its semaglutide, the active ingredient in both brands. This prompted Novo to cut its annual forecast and oust its CEO. Lilly's business appears to be holding up much better, according to analysts. They anticipate the proof will be in the quarterly results and outlook. What's more, several analysts expect other catalysts, including next-generation drugs, to help propel Lilly shares higher. 'Potential materiality' So far this year, Lilly's stock has logged a roughly 3% decline, underperforming the market. However, catalysts could come as soon as Thursday, analysts say. "We note that LLY's upcoming 2Q call is scheduled for 8:30am ET on Aug 7th, as opposed the company's standard 10am ET time slot for earnings calls after the market opens, suggesting potential materiality via topline trial results alongside earnings," Goldman Sachs analyst Asad Haider wrote in a July 28 research note. He said the report is "the most highly anticipated near-term event" across his pharmaceutical coverage. In addition to the financial outlook, investors are eager to hear more about orforglipron , the company's experimental GLP-1 pill. In June, at the American Diabetes Association conference, Lilly revealed the drug helped patients with type 2 diabetes in a late-stage trial lose weight without serious side effects . The readout of the phase 3 data for patients with obesity should be released soon. Wegovy's 'favored status' Analysts are also eager to hear management's thoughts on CVS Health 's policy of giving favored status to Wegovy over Lilly's Zepbound. The policy went into effect in July and means CVS Health's pharmacy benefit manager Caremark will prioritize Wegovy on its list of covered drugs. It has the potential to be a headwind for Lilly. However, patients may seek exemptions and remain on the weight loss drug or pay out of pocket on their own or via Lilly Direct, the company's direct-to-consumer website. Also, there is the possibility Lilly will strike a deal and get back on CVS Caremark's list of covered medications, analysts said. According to Bernstein analyst Courtney Breen, the first few weeks of the switch showed that patients changing from Zepbound to Wegovy was eclipsed by the number of patients starting the drug with a new prescription. On average, analysts surveyed by LSEG expect Lilly will earn $5.57 per share in the second quarter on revenue of $14.71 billion. If Lilly hits that revenue estimate, it will have achieved 30% growth year over year. Here's what else they're saying ahead of the report. LLY YTD mountain Eli Lilly shares year to date. Citigroup: Buy rating, $1,190 price target Citi analyst Geoff Meacham said Lilly remains one of its favorite stocks, and he placed a 90-day catalyst watch on it on July 30. His $1,190 price target implies 55% upside from Tuesday's close. "GLP-1 script data from IQVIA give us continued confidence in achievability of Lilly's 2025 revenue guidance ($58B-$61B). Notably, Zepbound scripts remain robust (+45% q/q) and overall share increased to 65.5%, representing a gain of ~600bps in market share. We think this is particularly noteworthy given vials from LillyDirect now represent ~20% of TRx [total prescriptions] and highlight increasing potential for a consumer angle in GLP-1 sales … driving uptake going forward (2Q25e $3.1B; +$99M vs. BBG cons). [Type 2 diabetes drug] Mounjaro scripts rose 16.3% q/q and now captures 42.2% share (2Q25e $4.5B; +$18M vs. cons); though slower growth than Zepbound, this is expected given the more entrenched nature of the type 2 diabetes market. … Top of mind for investors will be orforglipron's phase 3 ATTAIN readouts for obesity (Jul/Aug). Weight loss of 12-15% is the efficacy bar and continuation of a squeaky-clean safety profile that we saw at ADA for ACHIEVE … will be paramount." Morgan Stanley: Overweight, $1,135 In early July, Morgan Stanley analyst Terence Flynn tweaked his price target, increasing it to $1,135 from $1,133. The target suggests 48% upside. "In our view the magnitude of potential Mounjaro+Zepbound 2Q beat will dictate how LLY handles 2025 revenue guidance of $58-$61bn (MS $62.3bn vs. Cons $59.8bn), but we expect a raise of the low end at a minimum. LLY could also release Orfor Ph3 obesity and/or SURPASS-CVOT data in conjunction with earnings. … Interim Ph3 data for LLY's Kisunla in preclinical Alzheimer's (potentially later this year) could be a de-risking event for treating earlier in the disease course and expand the opportunity for the category, as well as provide lateral read-through to BIIB/Eisai's Leqembi (where Ph3 is also ongoing)" Bernstein: Outperform, $1,100 Bernstein, Wells Fargo and JPMorgan all have a $1,100 price target for Lilly's stock, which suggests it could rise nearly 44% from Tuesday's close. "We again see the potential for a meet or beat … , driven by Mounjaro & Zepbound performance. Given most of the street follow scripts closely in the US, the upside here arises from additional unexpected pricing (rebate adjustments), underreporting in IQVIA (a possibility), and ex-US performance (due to lower visibility). … Despite the potential for a top-line beat (we see potential for modest 1.2% beat above consensus at 14.6B), we don't anticipate LLY will be rushing to increase guidance, given last years back half challenges and the uncertainty for Q3 that remains on CVS caremark (although initial signs look strong)." Wells Fargo: Overweight, $1,100 "NVO lowering their guidance on Ozempic and Wegovy headwinds could be limited to NVO itself, as they cite continued compounding, competition, and slower market expansion. We believe LLY guidance can be raised on strong underlying trends. … Therefore, we would be buyers of LLY on the weakness since we expect a strong 2Q and a catalyst-rich 2H'25." JPMorgan: Overweight, $1,100 "Overall, we are expecting a solid 2Q for LLY with upside to Mounjaro/Zepbound (based on strong TRx growth trends), and we estimate total sales in the qtr of $14.8bn (+$370mm vs cons). On the EPS line, we are slightly below consensus ($5.49, -$0.06) as we expect a continued opex ramp to support a growing late stage pipeline and [direct-to consumer] initiatives. Looking forward, we expect some moderation in Zepbound growth as the CVS formulary change takes effect on July 1 but expect the product to still grow TRx in 3Q and accelerate in 4Q. And for the year, our estimates are near the high end of the company's 2025 guidance on both topline ($60.8bn sales, +$1.3bn vs cons) and the bottomline ($22.09 EPS, +$0.07 vs cons) and we would not be surprised to see LLY raise guidance at some point in 2025 (although the company may take a more conservative approach on the timing/magnitude of the increases given 2024 guidance dynamics)." Goldman Sachs: Buy, $883 Haider's $883 price target is about 15% above where Lilly shares closed on Tuesday. " … we expect another revenue beat, driven by an [foreign exchange] tailwind and strong TRx growth for Zepbound/Mounjaro where our and consensus estimates have tracked higher into the print. ... Into the 2Q earnings call, we also note significant investor discussion on the magnitude of potential upward pressure on the company's FY25 revenue guidance where we expect management could tighten the range of $58-$61bn for the year by bumping up the low-end (based on 1H trends, GS/consensus estimates are $60bn/$60.6bn for 2025). These trends are now well-understood with investor focus higher on trying to triangulate the impact to 3Q25 sales for Zepbound/Mounjaro from the CVS formulary change in favor of Novo that took effect on July 1st."
